Sinovac Biotech LTD revenue

Sinovac Biotech LTD's revenue was $386m in fiscal 2025, up 6.8% on the year before. Since fiscal 2009 ($84.2m) it has grown at a compound 13.5% a year.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Sinovac Biotech LTD: revenue history, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0.1	0.0	0.1	0.1	0.2	0.2	0.2	0.5	19.4	1.5	0.5	0.4	0.4
Growth on the year before	—	−60.3%	+70.2%	+27.4%	+140.7%	+31.7%	+7.1%	+107.5%	+>999%	−92.4%	−68.1%	−23.1%	+6.8%
Gross profit	0.1	0.0	0.0	0.1	0.2	0.2	0.2	0.4	18.4	0.8	0.3	0.2	0.3
Gross margin	76.2%	49.9%	62.8%	69.1%	88.4%	89.2%	86.8%	86.8%	94.9%	55.3%	68.8%	61.1%	67.9%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Sinovac Biotech LTD	$386m	6.8%	66.1%
Mannkind Corp	$394m	30.5%	35.5%
Pharming Group N.V.	$376m	26.6%	—
Meiragtx Holdings plc	$398m	948.3%	296.0%
Novavax Inc	$414m	-61.6%	-36.3%
Ardelyx, Inc.	$451m	16.8%	75.9%

Compare with peers

Head to head: MNKD vs SVA PHAR vs SVA MGTX vs SVA NVAX vs SVA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Sinovac Biotech LTD's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Sinovac Biotech LTD.